IFNL cytokines do not modulate human or murine NK cell functions

Human Immunology

Volumn 75, Issue 9, 2014, Pages 996-1000

  Morrison, Maria H ^a   Keane, Ciara ^a   Quinn, Louise M ^a   Kelly, Aoife ^a   O'Farrelly, Cliona ^a   Bergin, Colm ^b   Gardiner, Clair M ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b ST JAMES S HOSPITAL   (Ireland)

Author keywords

HCV; Interferon lambda; NK cells

Indexed keywords

INTERFERON; INTERFERON LAMBDA 3; INTERLEUKIN 28A; INTERLEUKIN 29; UNCLASSIFIED DRUG; GAMMA INTERFERON; IL28A PROTEIN, HUMAN; IL28B PROTEIN, HUMAN; IL29 PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE;

ANIMAL CELL; ARTICLE; CELL FUNCTION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; HUMAN; HUMAN CELL; IMMUNOMODULATION; LYMPHOCYTE ACTIVATION; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; ANIMAL; BLOOD; C57BL MOUSE; CELL CULTURE; DRUG EFFECTS; FLOW CYTOMETRY; HEPATITIS C; IMMUNOLOGY; K562 CELL LINE; METABOLISM;

ANIMALS; CELLS, CULTURED; FLOW CYTOMETRY; HEPATITIS C; HUMANS; INTERFERON-GAMMA; INTERLEUKINS; K562 CELLS; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; MICE, INBRED C57BL;

EID: 84923967270     PISSN: 01988859     EISSN: 18791166     Source Type: Journal    
DOI: 10.1016/j.humimm.2014.06.016     Document Type: Article

References (23)

1. Cornberg M., Razavi H.A., Alberti A., Bernasconi E., Buti M., Cooper C., et al. A systematic review of hepatitis c virus epidemiology in Europe, Canada and Israel. Liver Int 2011, 31(Suppl. 2):30-60.
2. Muhlberger N., Schwarzer R., Lettmeier B., Sroczynski G., Zeuzem S., Siebert U. HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortality. BMC Public Health 2009, 9:34.
3. Shepard C.W., Finelli L., Alter M.J. Global epidemiology of hepatitis c virus infection. Lancet Infect Dis 2005, 5:558-567.
4. Irshad M., Khushboo I., Singh S. Hepatitis c virus (HCV): a review of immunological aspects. Int Rev Immunol 2008, 27:497-517.
5. Dring M.M., Morrison M.H., McSharry B.P., Guinan K.J., Hagan R., O'Farrelly C., et al. Innate immune genes synergize to predict increased risk of chronic disease in hepatitis c virus infection. Proc Natl Acad Sci U S A 2011, 108:5736-5741.
6. Kenny-Walsh E. Clinical outcomes after hepatitis c infection from contaminated anti-D immune globulin. Irish hepatology research group. N Engl J Med 1999, 340:1228-1233.
7. Ge D., Fellay J., Thompson A.J., Simon J.S., Shianna K.V., Urban T.J., et al. Genetic variation in il28b predicts hepatitis c treatment-induced viral clearance. Nature 2009, 461:399-401.
8. Suppiah V., Moldovan M., Ahlenstiel G., Berg T., Weltman M., Abate M.L., et al. Il28b is associated with response to chronic hepatitis c interferon-alpha and ribavirin therapy. Nat Genet 2009, 41:1100-1104.
9. Thomas D.L., Thio C.L., Martin M.P., Qi Y., Ge D., O'Huigin C., et al. Genetic variation in il28b and spontaneous clearance of hepatitis c virus. Nature 2009, 461:798-801.
10. Keane C., O'Shea D., Reiberger T., Peck-Radosavljevic M., Farrell G., Bergin C., et al. Variation in both il28b and kir2ds3 genes influence pegylated interferon and ribavirin hepatitis c treatment outcome in hiv-1 co-infection. PLoS One 2013, 8:e66831.
11. Kramer B., Eisenhardt M., Glassner A., Korner C., Sauerbruch T., Spengler U., et al. Do lambda-interferons il28a and il28b act on human natural killer cells?. Proc Natl Acad Sci 2011.
12. Athie-Morales V., O'Connor G.M., Gardiner C.M. Activation of human NK cells by the bacterial pathogen-associated molecular pattern muramyl dipeptide. J Immunol 2008, 180:4082-4089.
13. Robek M.D., Boyd B.S., Chisari F.V. Lambda interferon inhibits hepatitis b and c virus replication. J Virol 2005, 79:3851-3854.
14. Doyle S.E., Schreckhise H., Khuu-Duong K., Henderson K., Rosler R., Storey H., et al. Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytes. Hepatology 2006, 44:896-906.
15. Marcello T., Grakoui A., Barba-Spaeth G., Machlin E.S., Kotenko S.V., MacDonald M.R. Interferons alpha and lambda inhibit hepatitis c virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology 2006, 131:1887-1898.
16. Kotenko S.V., Gallagher G., Baurin V.V., Lewis-Antes A., Shen M., Shah N.K., et al. IFN-lambdas mediate antiviral protection through a distinct class ii cytokine receptor complex. Nat Immunol 2003, 4:69-77.
17. Sheppard P., Kindsvogel W., Xu W., Henderson K., Schlutsmeyer S., Whitmore T.E. Il-28, il-29 and their class ii cytokine receptor il-28r. Nat Immunol 2003, 4:63-68.
18. Lasfar A., Lewis-Antes A., Smirnov S.V., Anantha S., Abushahba W., Tian B., et al. Characterization of the mouse IFN-lambda ligand-receptor system: IFN-lambdas exhibit antitumor activity against b16 melanoma. Cancer Res 2006, 66:4468-4477.
19. Bartlett N.W., Buttigieg K., Kotenko S.V., Smith G.L. Murine interferon lambdas (type iii interferons) exhibit potent antiviral activity in vivo in a poxvirus infection model. J Gen Virol 2005, 86:1589-1596.
20. Aparicio E., Parera M., Franco S., Perez-Alvarez N., Tural C., Clotet B., et al. Il28b snp rs8099917 is strongly associated with pegylated interferon-alpha and ribavirin therapy treatment failure in hcv/hiv-1 coinfected patients. PLoS One 2010, 5:e13771.
21. Prokunina-Olsson L., Muchmore B., Tang W., Pfeiffer R.M., Park H., Dickensheets H., et al. A variant upstream of ifnl3 (il28b) creating a new interferon gene ifnl4 is associated with impaired clearance of hepatitis c virus. Nat Genet 2013.
22. Tanaka Y., Nishida N., Sugiyama M., Kurosaki M., Matsuura K., Sakamoto N., et al. Genome-wide association of il28b with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis c. Nat Genet 2009, 41:1105-1109.
23. Kramer B., Eisenhardt M., Glassner A., Korner C., Sauerbruch T., Spengler U., et al. Do lambda-ifns il28a and il28b act on human natural killer cells?. Proc Natl Acad Sci U S A 2011, 108:E519-E520. author reply E521-512.